Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis

Chest

Volumn 145, Issue 1, 2014, Pages 108-112

  Cai, Xiong ^a   Pacheco Rodriguez, Gustavo ^a   Haughey, Mary ^a   Samsel, Leigh ^b   Xu, Suowen ^a   Wu, Hai Ping ^a   McCoy, J Philip ^b   Stylianou, Mario ^a   Darling, Thomas N ^c   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD235A ANTIBODY; CD45 ANTIBODY; CD45 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; PHYCOERYTHRIN; RAPAMYCIN; TUBERIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CELL CULTURE; CELL FRACTIONATION; CELL ISOLATION; CELL SELECTION; CENTRIFUGATION; CHYLE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE IDENTIFICATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LYMPHANGIOLEIOMYOMATOSIS; PRIORITY JOURNAL; TSC2 GENE; URINALYSIS;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; SIROLIMUS; TUMOR SUPPRESSOR PROTEINS;

EID: 84892661539     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1071     Document Type: Article

References (18)

1. Ryu JH, Moss J, Beck GJ, et al NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006; 173 (1): 105-111.
2. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000; 97 (11): 6085-6090.
3. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002; 277 (34): 30958-30967.
4. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008; 412 (2): 179-190.
5. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149 (2): 274-293.
6. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011; 10 (11): 868-880.
7. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358 (2): 140-151.
8. McCormack FX, Inoue Y, Moss J, et al National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364 (17): 1595-1606.
9. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002; 8 (2): 128-135.
10. Zhou H, Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci. 2011; 12 (1): 30-42.
11. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011 ;154(12):797-805.
12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000; 103 (2): 253-262.
13. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2004; 101 (50): 17462-17467.
14. Cai X, Pacheco-Rodriguez G, Fan QY, et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2010; 182 (11): 1410-1418.
15. Pacheco-Rodriguez G, Steagall WK, Crooks DM, et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res. 2007; 67 (21): 10573-10581.
16. European Chromosome 16 Tuberous Sclerosis Con sortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993; 75 (7): 1305-1315.
17. Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A. 2009; 106 (8): 2635-2640.
18. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351 (8): 781-791.